News & Topics Past News
2017.11.13
Initiation of an Arbitration against The Medicines Company
2017.11.10
Analyst Report[Update report]: Shared Research updates the report
2017.11.10
Notice Concerning Non-operating Income
2017.11.10
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated)
2017.11.02
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting
2017.10.23
Analyst Report: Edison updates the report
2017.10.16
Analyst Report[Full report]: Shared Research updates the report
2017.10.10
Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.09.21
Analyst Report[Update report]: Shared Research updates the report
2017.09.21
Notice of Revision to the Earnings Forecast for FY2017
2017.09.21
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
2017.09.20
Analyst Report[Full report]: Shared Research updates the report
2017.08.31
Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2017.08.30
Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
2017.08.25
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.08.03
Analyst Report[Update report]: Shared Research updates the report
2017.08.03
Notice Concerning Non-operating Income
2017.08.03
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
2017.07.26
Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies"
2017.07.05
Dr. Koichi Takahashi, Assistant Professor, The University of Texas MD Anderson Cancer Center, has been appointed as a member of the SAB.
2017.06.30
Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.06.05
SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.06.05
Analyst Report[Full report]: Shared Research updates the report
2017.05.11
Analyst Report[Update report]: Shared Research updates the report